Accessibility Menu
aTyr Pharma logo

aTyr Pharma(NASDAQ) ATYR

Current Price$0.49
Market Cap$47.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-100%
5 Year-89%
1 Year-91%
1 Month+4%
aTyr Pharma last closing stock price
MetricPriceDate
Last closeUSD 0.492026-07-22
aTyr Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-8.85%USD 0.532026-07-15
1 month+3.57%USD 0.472026-06-22
3 month-38.49%USD 0.792026-04-23
Year to date-37.81%USD 0.782025-12-31
1 year-90.71%USD 5.242025-07-22
3 year-76.47%USD 2.072023-07-21
5 year-89.08%USD 4.462021-07-23
Since inception-99.82%USD 269.782015-05-08

aTyr Pharma Financials at a Glance

Market Cap

$47.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$190.00K

Net Income (TTM)

-$70.03M

EPS (TTM)

-$0.73

P/E Ratio

-0.66

Dividend

$0.00

Beta (Volatility)

0.86 (Low)

Price

$0.49

Volume

0

Open

$0.49

Previous Close

$0.49

Daily Range

$0.48 - $0.51

52-Week Range

$0.40 - $7.29

Estimated Earnings Date

Aug 6, 2026

ATYR News

research scientists drugs pharma biotech

1 Small-Cap Biotech Stock Poised for a Breakout

Prosper Junior BakinySep 11, 2025
getty-happy-couple-on-couch-fistpump-smiling

2 Small-Cap Biotech Stocks Well Positioned for a Breakout

Cory RenauerAug 27, 2025
GettyImages-1305098938

1 Small-Cap Biotech Stock Poised for a Breakout

George Budwell, PhDAug 6, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About aTyr Pharma

aTyr develops medicines for rare lung and immune diseases. Its main drug aims to help people with lung inflammation. The company focuses on patients with few existing treatment options.

Lab Bench to Bedside: aTyr’s Main Offerings

  • Efzofitimod (Lead Drug): In late-stage trials for lung diseases like pulmonary sarcoidosis; targets immune system pathways. 0% of revenue in Q2 2025.
  • ATYR0101 (Preclinical): Early-stage drug for tissue scarring (fibrosis); not yet tested in humans. 0% of revenue in Q2 2025.
  • ATYR0750 (Preclinical): Early-stage drug for liver disorders; still in laboratory development. 0% of revenue in Q2 2025.
  • Research Collaborations: Partnership with Kyorin Pharmaceutical in Japan for lung disease drug development. 100% of revenue in Q2 2025.

Growth Spurts and Strategic Moves

  • Signed exclusive licensing deal with Kyorin Pharmaceutical for Japan in 2020.
  • Completed global Phase III trial enrollment for efzofitimod in July 2024.
  • Expanded manufacturing with a new contract partner in 2025.
  • Launched expanded access program for patients in 2024.

Why aTyr Is a Bit Different

aTyr uses a unique approach based on tRNA synthetase biology, a less-explored area in drug development. Its focus is on rare diseases with few treatments, using both internal research and external partnerships. The company operates mainly in the US, with a key collaboration in Japan.

Five Things You Need to Know

  • No product sales; $0 revenue in Q2 2025.
  • Net loss was $20 million in Q2 2025, down 17.3% from Q2 2024.
  • Cash and investments totaled $83.2 million as of June 30, 2025.
  • Operating expenses rose to $20.3 million in Q2 2025, up 17.3% year-on-year.
  • 56 full-time employees as of June 2025; market cap $75.48 million.

Bottom Line

aTyr remains focused on developing new drugs for rare lung and immune diseases. The company relies on research partnerships and equity funding, with no commercial products yet.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

58

CEO

Sanjay S. Shukla, MD

Website

www.atyrpharma.com

Headquarters

San Diego, CA 92121, US

ATYR Financials

Key Financial Metrics (TTM)

Gross Margin

-11754.74%

Operating Margin

-38573.68%

Net Income Margin

-36857.37%

Return on Equity

-99.87%

Return on Capital

-97.63%

Return on Assets

-87.92%

Earnings Yield

-1.52%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$47.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

98.05M

Volume

0

Avg. Volume

2.77M

Financials (TTM)

Gross Profit

-$22.33M

Operating Income

-$73.29M

EBITDA

-$68.69M

Operating Cash Flow

-$59.08M

Capital Expenditure

-$215.00K

Free Cash Flow

-$59.30M

Cash & ST Invst.

$66.51M

Total Debt

$11.70M

aTyr Pharma Performance Analysis

aTyr Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 10,386,000N/A
20232023-12-31USD 353,000-96.6%
20242024-12-31USD 235,000-33.4%
20252025-12-31USD 190,000-19.1%
aTyr Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31-100.0%
Q12026-03-31N/A
aTyr Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.60-9.9%
20232023-12-31USD -0.94-41.1%
20242024-12-31USD -0.86-8.3%
20252025-12-31USD -0.80-7.5%
aTyr Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-29.4%
Q32025-09-30-18.2%
Q42025-12-3146.2%
Q12026-03-3121.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$394.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$47.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$823.29K

N/A

Employees

58

N/A

Net Income

-$10.79M

+27.5%

EBITDA

-$10.40M

+28.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$66.51M

-12.9%

Total Debt

$11.70M

-9.9%

Accounts Receivable

$477.00K

-51.7%

Inventory

$0.00

N/A

Long Term Debt

$10.21M

-12.7%

Short Term Debt

$1.49M

+15.2%

Return on Assets

-87.92%

N/A

Return on Invested Capital

-1.08%

N/A

Free Cash Flow

-$12.66M

+17.9%

Operating Cash Flow

-$12.52M

+18.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MGXMetagenomi, Inc. Common Stock
$1.24+1.64%
ACRVAcrivon Therapeutics, Inc. Common Stock
$1.68-4.00%
CAMPCAMP4 Therapeutics Corporation
$3.11-2.51%
HYFTMindWalk Holdings Corp.
$1.44-1.37%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.28-0.03%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
INTCIntel
$102.62-0.03%
AALAmerican Airlines Group
$14.79-0.03%

Questions About ATYR

What is the current price of aTyr Pharma?

aTyr Pharma is trading at $0.49 per share.

What is the 52-week range for aTyr Pharma?

Over the past 52 weeks, aTyr Pharma has traded between $0.40 and $7.29.

How much debt does aTyr Pharma have?

As of the most recent reporting period, aTyr Pharma reported total debt of $11.70M.

How much cash does aTyr Pharma have on hand?

aTyr Pharma reported $10.01M in cash and cash equivalents in its most recent financial results.

What is aTyr Pharma’s dividend yield?

aTyr Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services